To the Editor: I wholeheartedly endorse Benca and colleagues’ conclusion, in their recent review on obstructive sleep apnea (OSA) in psychiatric practice,1 “Clinicians should not assume that all sleep-related symptoms are consequences of psychiatric illness or medication but should instead be cognizant of the potential for coexisting OSA that requires treatment.” This view aligns with our 2002 hypothesis-generating review that challenged the nonspecific terminology “psychiatric insomnia” or “insomnia related to another mental disorder” for its failure to consider nosologically defined sleep disorders.2 From the mid-1990s to early 2000s, my colleagues and I observed extensive, objectively measured, physiological sleep quality disruptions in psychiatric patients presenting with psychological sleep disorders, insomnia, or nightmares. Hence, Dr Christian Guilleminault and colleagues3 as well as our research team published on 4 chronic insomnia patient cohorts totaling 703 adults, of whom 603 were objectively diagnosed (n = 427) or presumptively diagnosed (n = 176) with sleep-disordered breathing (SDB).2 In earlier times4 as well as more recently, several research groups5-8 have observed high SDB prevalence among patients presenting with chief complaints of insomnia.
In 2003, our new center specializing in sleep disorders treatment for mental health patients was acutely exposed to the frustrating problem of continuous positive airway pressure (CPAP) failure. Like others, we presumed novel and intrusive stimuli of mask and pressurized air caused psycho-physiological maladaptation, largely aggravated by somatosensory amplification, not to mention the disincentivizing emotions of embarrassment and shame frequently triggered in psychiatric patients. Subsequently, we developed PAP-NAP procedures to create a systematic desensitization to mask and pressure for anxiety, depression, and posttraumatic stress disorder patients with coexisting insomnia or nightmares. The PAP-NAP approach was beneficial for many patients.9
Through the 2000s, we turned toward physiological disturbances caused by CPAP, primarily expiratory pressure intolerance (EPI), and observed how this uncomfortable, unpleasant stimulus carried an outsized clinical impact on CPAP failure with its notable associations to excessive sleep stage shifts, sleep fragmentation, lack of REM consolidation, and unresolvable respiratory effort-related arousals.10 To address these objective changes due to EPI, in 2005 we transitioned virtually all of our PAP patients to bilevel mode, and by 2010 auto-bilevel mode, and finally by 2012 roughly two-thirds of our patients used auto-bilevel and one-third used ASV (adaptive servo-ventilation).11 Research followed, demonstrating how advanced PAP technology rescues CPAP failure cases, improves outcomes, and increases adherence.12–14 Recently, a randomized controlled trial proved ASV significantly and clinically superior to CPAP in treating chronic insomnia, yielding nearly thrice as many insomnia “cures,” based on Insomnia Severity Index (ISI) scores (mean exit ISI with ASV = 5.89 vs CPAP = 10.19; ISI “cure” cutoff = 8; P = .01).8 Although the total sample was small (n = 40), limiting significance findings, large effect sizes for ASV were demonstrated within-group compared to small-medium effects for CPAP on 3 validated scales measuring fatigue, quality of life, and daytime impairment, plausible outcomes consistent with growing evidence that independent sleep disorders therapy improves mental health.14
In sum, in our clinical experiences SDB is widespread in psychiatric patients and should be screened at intake; unfortunately, all such instruments were designed for classic sleep apnea and yield high false negative rates.9 Our recommendation since 2005 assumes “guilty until proven innocent” with regard to the presence of SDB, as we test greater than 90% of mental health patients who present with a complaint of chronic insomnia or nightmares. It is our opinion that failing to test led many psychiatric patients to suffer inordinate harm for a decade or longer when pharmacotherapy remained their only sleep option.15
As we concluded in 2002 and now 21 years later, I would ask 2 questions: (1) In non-urgent cases, would it be advisable to objectively assess sleep and respiration prior to prescribing sedatives or sedating psychotropic medication? and (2) What are the potential liability issues that might arise when insomnia patients with SDB do not receive appropriate diagnostic testing?2
It is our belief that patients seeking sleep treatments from mental health professionals deserve answers to these questions.
Krakow B, Melendrez D, Warner TD, et al. To breathe, perchance to sleep: sleep-disordered breathing and chronic insomnia among trauma survivors. Sleep Breath. 2002;6(4):189–202. PubMedCrossRef
Guilleminault C, Palombini L, Poyares D, et al. Chronic insomnia, postmenopausal women, and sleep disordered breathing: part 1. Frequency of sleep disordered breathing in a cohort. J Psychosom Res. 2002;53(1):611–615. PubMedCrossRef
Guilleminault C, Eldridge FL, Dement WC. Insomnia with sleep apnea: a new syndrome. Science. 1973;181(4102):856–858. PubMedCrossRef
Lichstein KL, Riedel BW, Lester KW, et al. Occult sleep apnea in a recruited sample of older adults with insomnia. J Consult Clin Psychol. 1999;67(3):405–410. PubMedCrossRef
Lack L, Sweetman A. Diagnosis and treatment of insomnia comorbid with obstructive sleep apnea. Sleep Med Clin. 2016;11(3):379–388. PubMedCrossRef
Sweetman A, Osman A, Lack L, et al. Co-morbid insomnia and sleep apnea (COMISA): recent research and future directions. Curr Opin Pulm Med. 2023;29(6):567–573; Epub ahead of print. PubMedCrossRef
Ye L, Pien GW, Ratcliffe SJ, et al. The different clinical faces of obstructive sleep apnoea: a cluster analysis. Eur Respir J. 2014;44(6):1600–1607. PubMedCrossRef
Ulibarri VA, Krakow B, McIver ND. The PAP-NAP one decade later: patient risk factors, indications, and clinically relevant emotional and motivational influences on PAP use. Sleep Breath. 2020;24(4):1427–1440. PubMedCrossRef
Krakow B, Ulibarri VA, Romero EA, et al. Adaptive servoventilation therapy in a case series of patients with co-morbid insomnia and sleep apnea. J Sleep Disord Treat Care. 2013;2(1):1–10. CrossRef
Krakow B, Ulibarri VA, McIver ND, et al. Reversal of PAP failure with the REPAP protocol. Respir Care. 2017;62(4):396–408. PubMedCrossRef
Krakow BJ, McIver ND, Obando JJ, et al. Changes in insomnia severity with advanced PAP therapy in patients with posttraumatic stress symptoms and comorbid sleep apnea: a retrospective, nonrandomized controlled study. Mil Med Res. 2019;6(1):15. PubMedCrossRef
Krakow BJ, Obando JJ, Ulibarri VA, et al. Positive airway pressure adherence and subthreshold adherence in posttraumatic stress disorder patients with comorbid sleep apnea. Patient Prefer Adherence. 2017;11:1923–1932. PubMedCrossRef
Krakow B, McIver ND, Ulibarri VA, et al. Prospective randomized controlled trial on the efficacy of continuous positive airway pressure and adaptive servo-ventilation in the treatment of chronic complex insomnia. EClinicalMedicine. 2019;13:57–73. PubMedCrossRef
Krakow B, Ulibarri VA, McIver ND. Pharmacotherapeutic failure in a large cohort of patients with insomnia presenting to a sleep medicine center and laboratory: subjective pretest predictions and objective diagnoses. Mayo Clin Proc. 2014;89(12):1608–1620. PubMedCrossRef